UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?

Clinical and applied thrombosis/hemostasis, 2022-01, Vol.28, p.10760296221096422-10760296221096422

Walenga, Jeanine M.

2022

Volltextzugriff (PDF)

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Clinical and Applied Thrombosis/Hemostasis, 2021, Vol.27, p.10760296211021498

2021

Volltextzugriff (PDF)

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

Clinical and applied thrombosis/hemostasis, 2020, Vol.26, p.107602962095972-1076029620959724

2020

Volltextzugriff (PDF)

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

Thrombosis journal, 2013-04, Vol.11 (1), p.7-7

2013

Volltextzugriff (PDF)

The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting

Thrombosis research, 2024-07, Vol.239, p.109023-109023, Article 109023

2024

Volltextzugriff (PDF)

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

International immunology, 2002-02, Vol.14 (2), p.121-129

2002

Volltextzugriff (PDF)

Heparin-induced thrombocytopenia: an update

Seminars in thrombosis and hemostasis, 2012-07, Vol.38 (5), p.483-496

2012

Volltextzugriff (PDF)

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer

Critical reviews in oncology/hematology, 2013-10, Vol.88 (1), p.1-18

2013

Volltextzugriff (PDF)

Heparin: Much more than anti-IIa/anti-Xa

Journal de médecine vasculaire, 2020-05, Vol.45 (3), p.103-104

Walenga, Jeanine M.

2020

Volltextzugriff (PDF)

Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients

Thrombosis research, 2012-04, Vol.129 (4), p.474-478

2012

Volltextzugriff (PDF)

Evaluation of Circuit and AV Fistula Clotting and Detection of Anti-PF4/Heparin Complex Antibodies in Hemodialysis Patients Suspected of Having Heparin-Induced Thrombocytopenia

Clinical and applied thrombosis/hemostasis, 2013-01, Vol.19 (1), p.73-78

2013

Volltextzugriff (PDF)

Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

ASAIO journal (1992), 2023-03, Vol.69 (3), p.278-283

2023

Volltextzugriff (PDF)

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

American Journal of Physiology: Cell Physiology, 2010-07, Vol.299 (1), p.C97-C110

2010

Volltextzugriff (PDF)

The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia

Hematology/oncology clinics of North America, 2008-02, Vol.22 (1), p.1-18

2008

Volltextzugriff (PDF)

Sulodexide for the extended treatment of venous thromboembolism

International angiology, 2016-12, Vol.35 (6), p.531

2016

Volltextzugriff (PDF)

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels

Blood coagulation & fibrinolysis, 2011-04, Vol.22 (3), p.206-210

2011

Volltextzugriff (PDF)

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

Expert opinion on investigational drugs, 2002-03, Vol.11 (3), p.397-407

2002

Volltextzugriff (PDF)

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update

Seminars in thrombosis and hemostasis, 2008-02, Vol.34 (1), p.86-96

2008

Volltextzugriff (PDF)

Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia

British journal of haematology, 2008-10, Vol.143 (1), p.92-99

2008

Volltextzugriff (PDF)

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

Clinical and applied thrombosis/hemostasis, 2018-09, Vol.24 (6), p.965-972

2018

Volltextzugriff (PDF)

Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

Clinical and applied thrombosis/hemostasis, 2018-12, Vol.24 (9_suppl), p.294S-300S

2018

Volltextzugriff (PDF)

In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative

Clinical and applied thrombosis/hemostasis, 2010-08, Vol.16 (4), p.377-386

2010

Volltextzugriff (PDF)

Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices

Biomarkers in medicine, 2016-10, Vol.10 (10), p.1095-1104

2016

Volltextzugriff (PDF)

Heparin-Induced Thrombocytopenia: A Serious Complication of Heparin Therapy for Acute Stroke

Cerebrovascular diseases (Basel, Switzerland), 2008-01, Vol.26 (6), p.641-649

2008

Volltextzugriff (PDF)

1 – 25 von 391

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(375)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Englisch
(387)
Japanisch
(31)
Deutsch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(211)
Science & Technology
(211)
Humans
(179)
Cardiovascular System & Cardiology
(162)
Hematology
(159)
Peripheral Vascular Disease
(146)
Biological And Medical Sciences
(86)
Medical Sciences
(81)
Male
(71)
Animals
(62)
Female
(57)
Heparin - Adverse Effects
(54)
Pharmacology. Drug Treatments
(54)
Thrombocytopenia - Chemically Induced
(54)
Anticoagulants
(52)
Heparin
(46)
Blood. Blood Coagulation. Reticuloendothelial System
(38)
Anticoagulants - Therapeutic Use
(35)
Adult
(32)
Heparin - Pharmacology
(32)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Can We Improve on the Rapid Assessment of Clinically Relevant Levels of Direct Acting Oral Anticoagulants (DOAC)?

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination

Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia

The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting

Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells

Heparin-induced thrombocytopenia: an update

Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer

Heparin: Much more than anti-IIa/anti-Xa

Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients

Evaluation of Circuit and AV Fistula Clotting and Detection of Anti-PF4/Heparin Complex Antibodies in Hemodialysis Patients Suspected of Having Heparin-Induced Thrombocytopenia

Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study

Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands

The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia

Sulodexide for the extended treatment of venous thromboembolism

Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update

Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence

Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopenia

Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device

Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes

In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative

Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices

Heparin-Induced Thrombocytopenia: A Serious Complication of Heparin Therapy for Acute Stroke

Suchergebnisse filtern